Biotage AB (publ)

OM:BIOT Stock Report

Market Cap: SEK 12.7b

Biotage Future Growth

Future criteria checks 3/6

Biotage is forecast to grow earnings and revenue by 19.5% and 12.1% per annum respectively. EPS is expected to grow by 19.6% per annum. Return on equity is forecast to be 11.1% in 3 years.

Key information

19.5%

Earnings growth rate

19.6%

EPS growth rate

Life Sciences earnings growth43.6%
Revenue growth rate12.1%
Future return on equity11.1%
Analyst coverage

Low

Last updated13 Dec 2024

Recent future growth updates

Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts

Oct 26
Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts

Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Jul 19
Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Recent updates

Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 48%?

Nov 16
Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 48%?

Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts

Oct 26
Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts

Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Sep 17
Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings

Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Jul 19
Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next

Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?

Jun 08
Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?

Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?

May 21
Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?

Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Apr 28
Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Biotage's (STO:BIOT) Dividend Will Be SEK1.60

Apr 17
Biotage's (STO:BIOT) Dividend Will Be SEK1.60

Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Apr 08
Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Apr 03
Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Mar 04
Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60

Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Feb 22
Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)

Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%

Feb 21
Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%

Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Feb 18
Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next

Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet

Feb 08
Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet

Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)

Jan 07
Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)

At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?

Dec 08
At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?

Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)

Oct 27
Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)

Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

Jul 12
Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued

Jun 08
An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued

Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth

May 24
Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 05
Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely

Mar 12
These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely

Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?

Feb 21
Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?

Are Biotage AB (publ) (STO:BIOT) Investors Paying Above The Intrinsic Value?

Jan 06
Are Biotage AB (publ) (STO:BIOT) Investors Paying Above The Intrinsic Value?

Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly

Dec 03
Biotage (STO:BIOT) Seems To Use Debt Rather Sparingly

Is Now The Time To Look At Buying Biotage AB (publ) (STO:BIOT)?

Oct 27
Is Now The Time To Look At Buying Biotage AB (publ) (STO:BIOT)?

Estimating The Fair Value Of Biotage AB (publ) (STO:BIOT)

Oct 07
Estimating The Fair Value Of Biotage AB (publ) (STO:BIOT)

Biotage (STO:BIOT) Could Easily Take On More Debt

Sep 03
Biotage (STO:BIOT) Could Easily Take On More Debt

Is There Now An Opportunity In Biotage AB (publ) (STO:BIOT)?

Jul 10
Is There Now An Opportunity In Biotage AB (publ) (STO:BIOT)?

A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)

Jun 25
A Look At The Fair Value Of Biotage AB (publ) (STO:BIOT)

Do Biotage's (STO:BIOT) Earnings Warrant Your Attention?

May 28
Do Biotage's (STO:BIOT) Earnings Warrant Your Attention?

Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Apr 23
Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's

Earnings and Revenue Growth Forecasts

OM:BIOT - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262,7574755386693
12/31/20252,4573553144773
12/31/20242,1562552653933
9/30/20242,117257243406N/A
6/30/20242,077251261399N/A
3/31/20241,981236268381N/A
12/31/20231,862246193284N/A
9/30/20231,603189148229N/A
6/30/20231,554216147223N/A
3/31/20231,541240220295N/A
12/31/20221,566268271341N/A
9/30/20221,524240285346N/A
6/30/20221,428228285338N/A
3/31/20221,337216290342N/A
12/31/20211,232205297353N/A
9/30/20211,188203273336N/A
6/30/20211,145187256321N/A
3/31/20211,096174222286N/A
12/31/20201,092175218279N/A
9/30/20201,083149213268N/A
6/30/20201,103179221274N/A
3/31/20201,131201211260N/A
12/31/20191,101187166212N/A
9/30/20191,047196145187N/A
6/30/2019997173112158N/A
3/31/201995117094139N/A
12/31/2018911168108155N/A
9/30/2018865175120170N/A
6/30/2018811162N/A149N/A
3/31/2018771148N/A168N/A
12/31/2017748139N/A169N/A
9/30/2017738122N/A145N/A
6/30/2017728118N/A145N/A
3/31/2017694105N/A131N/A
12/31/201666893N/A139N/A
9/30/201665796N/A130N/A
6/30/201664087N/A133N/A
3/31/201662578N/A133N/A
12/31/201561173N/A120N/A
9/30/201558083N/A116N/A
6/30/201554975N/A98N/A
3/31/201552175N/A94N/A
12/31/201449065N/A81N/A
9/30/201447453N/A72N/A
6/30/201445949N/A70N/A
3/31/201445546N/A52N/A
12/31/201344541N/A57N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIOT's forecast earnings growth (19.5% per year) is above the savings rate (1.2%).

Earnings vs Market: BIOT's earnings (19.5% per year) are forecast to grow faster than the Swedish market (14.6% per year).

High Growth Earnings: BIOT's earnings are forecast to grow, but not significantly.

Revenue vs Market: BIOT's revenue (12.1% per year) is forecast to grow faster than the Swedish market (1.2% per year).

High Growth Revenue: BIOT's revenue (12.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BIOT's Return on Equity is forecast to be low in 3 years time (11.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 01:52
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biotage AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
Odysseas ManesiotisBerenberg
Marcus BellanderCarnegie Investment Bank AB